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Silver nanoparticles are known to be distributed in many tissues after oral or inhalation exposure. Thus,
understanding the tissue clearance of such distributed nanoparticles is very important to understand the behavior
of silver nanoparticles in vivo. For risk assessment purposes, easy clearance indicates a lower overall cumulative
toxicity. Accordingly, to investigate the clearance of tissue silver concentrations following oral silver nanoparticle
exposure, Sprague–Dawley rats were assigned to 3 groups: control, low dose (100 mg/kg body weight), and high
dose (500 mg/kg body weight), and exposed to two different sizes of silver nanoparticles (average diameter 10 and
25 nm) over 28 days. Thereafter, the rats were allowed to recover for 4 months. Regardless of the silver nanoparticle
size, the silver content in most tissues gradually decreased during the 4-month recovery period, indicating tissue
clearance of the accumulated silver. The exceptions were the silver concentrations in the brain and testes, which
did not clear well, even after the 4-month recovery period, indicating an obstruction in transporting the
accumulated silver out of these tissues. Therefore, the results showed that the size of the silver nanoparticles did
not affect their tissue distribution. Furthermore, biological barriers, such as the blood–brain barrier and blood-testis
barrier, seemed to play an important role in the silver clearance from these tissues.
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Among nanomaterials, the commercial application of sil-
ver nanoparticles is the most widespread, where their anti-
microbial activity has been applied to bedding, washing
machines, water purification, toothpaste, shampoo and
rinse, nipples and nursing bottles, fabrics, deodorants, fil-
ters, kitchen utensils, toys, and humidifiers [1]. Silver
nanoparticles have also been added to medical products,
including wound dressings, contraceptives, surgical instru-
ments, bone prostheses, and cardiac catheters [2,3].
In previous research, the target organs for silver
nanoparticles have been shown to be the liver in a 28-day
oral toxicity study [4] and 90-day oral subchronic study
[5], and the liver and lungs in 90-day inhalation studies
[6,7]. As a result, these studies set the NOAEL at 30 mg/
kg/body weight [4,5] in the 28-day oral toxicity study and
90-day oral subchronic study, and 100 μg/m3 [6] and* Correspondence: u1670916@chollian.net
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reproduction in any medium, provided the or117 μg/m3 [7] in the 90-day inhalation study and 12-week
toxicity study, respectively. Further studies have also found
that silver originating from silver nanoparticles is distrib-
uted in all tissues, including the liver, kidneys, lungs,
spleen, brain, blood, ovaries, and testes [8-10]. A gender-
related distribution of silver in the kidneys was also con-
sistent in the results from the abovementioned 28-day, 90-
day, and 12-week inhalation studies [4,6,7] and 90-day oral
studies [5]. Thus, the clearance behavior is an important
determinant for predicting the chronic effects of tissue-
accumulated silver nanoparticles. Several studies have
already investigated the clearance of tissue-accumulated
silver following iv (intravenous) or oral exposure to differ-
ent sizes of silver nanoparticles and silver ions, for ex-
ample, following 5 days of iv exposure to 17 days post
exposure [8], following 28 days of oral exposure to 8 weeks
post exposure [9], and following 90 days of inhalation ex-
posure to 90 days post exposure [7]. However, there has
been no long-term post exposure study of the clearance
kinetics of tissue-accumulated silver following subacute
oral silver nanoparticle exposure. Accordingly, in this. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lee et al. Particle and Fibre Toxicology 2013, 10:36 Page 2 of 14
http://www.particleandfibretoxicology.com/content/10/1/36study, rats were administered silver nanoparticles orally
for 28 days and allowed to recover for four months to
identify the clearance of the tissue-accumulated silver.
Materials and methods
Silver nanoparticles
The colloidal silver nanoparticles (CAS No. 7440-22-4)
were purchased from ABC Nanotech (Daejeon, Korea) and
were at least 99.98% pure. The silver nanoparticles were
synthesized based on an inductive coupled plasma (ICP)
method using a precursor, such as silver wire. The silver
nanoparticles were then immediately stabilized using citrate
(0.9%). The detailed synthesis process is described in Lee
et al. [11]. The percentage of silver ions in the silver nano-
particle preparations was determined by centrifugation
through a cellulose filter with a nominal cutoff value of
3 kDa (Ultra-4, Amicon, Millipore, Germany). The total sil-
ver content in the unfiltered silver nanoparticle suspensions
and their respective filtrates was measured using ICP-MS.
The percentage of soluble silver in the silver nanoparticle
suspensions was calculated by dividing the silver content in
the filtrates by the silver content in the unfiltered silver
nanoparticle suspensions multiplied by 100 [9].
Transmission electron microscopy
The silver nanoparticles in the 0.9% citrate solution were
filtered using filters coated with carbon, mounted on an
electron microscope grid (200 mesh, Veco, Eerbeek,
Holland), and visualized under a transmission electron
microscope (TEM, Hitachi 7100). The diameters of 800
(for 10 nm) and 500 (for 25 nm) randomly selected par-
ticles were measured at a magnification of 50,000, and
the silver particles analyzed using an energy-dispersive
x-ray analyzer (EDX-200, Horiba, Japan) at an accelerat-
ing voltage of 75 kV.
Animals and conditions
Four-week-old male and female, specific-pathogen free
(SPF) Sprague Dawley rats were purchased from Orient Bio
(Korea) and acclimated for 7 days before starting the exper-
iments. During the acclimation and experimental periods,
the rats were housed in polycarbonate cages (maximum of
3 rats per cage) in a room with controlled temperature
(22.2 ± 1.7°C) and humidity (48.4 ± 6.0%), and a 12-h light/
dark cycle. The rats were fed a rodent diet (Harlan Labora-
tories Inc., USA) and filtered water ad libitum. The rats
were divided into 3 groups (20 rats in each group): vehicle
control (0.9% citrate), low-dose group (100 mg/kg/day),
and high-dose group (500 mg/kg/day). After reaching five
weeks of age, the rats were exposed to silver nanoparticles
(suspended in 0.9% citrate) for 4 weeks (once/day, 7 days/
week) via repeated gavage feeding (dosing volumes were
5 ml/kg). The nanoparticles were freshly prepared every
day based on the rat body weights and used immediately.The dose levels were selected based on previous observa-
tions from a 28-day oral toxicity study by Kim et al. [4].
The administration of silver nanoparticles was ceased after
28 days, and the rats allowed to recover. Animals were
sacrificed at the end of the exposure, and 1, 2, and 4 months
after ceasing the silver nanoparticle exposure to investigate
the clearance of the tissue-accumulated silver. The ex-
periment was approved by the KCL Institutional Animal
Care and Use Committee according to the Korean Animal
Care Act.
Biochemical, hematological, and histopathological
evaluation
Food was withheld for 24 h before necropsy at the conclu-
sion of the 28-day oral administration and after 1, 2, and
4 months of recovery, and the rats anesthetized with
pentoparbital. Blood was then drawn from the abdominal
aorta, collected in heparinized vacutainers, and analyzed
for ALB (albumin), ALP (alkaline phosphatase), Ca (cal-
cium), CHO (cholesterol), CRE (creatinine), gamma-GT
(gamma-glutamyl transpeptidase), GLU (glucose), GOT
(glutamic oxalacetic transaminase), GPT (glutamic pyruvic
transaminase), IP (inorganic phosphorus), LDH (lactate
dehydrogenase), Mg (magnesium), TP (total protein), UA
(uric acid), BUN (blood urea nitrogen), TBIL (total biliru-
bin), CK (creatine phosphokinase), Na (sodium),K(potas-
sium), Cl (chloride), TG (triglyceride), and A/G (ratio of
albumin to globulin) using a biochemical blood analyzer
(Hitachi 7180, Hitachi, Japan). The WBC (white blood cell
count), RBC (red blood cell count), Hb (hemoglobin con-
centration), HTC (hematocrit), MCV (mean corpuscular
volume), MCH (mean corpuscular hemoglobin), MCHC
(mean corpuscular hemoglobin concentration), RDW (red
cell distribution width), PLT (platelet count), MPV (mean
platelet volume), NE# (number of neutrophils), NE% (per-
cent of neutrophils), LY# (number of lymphocytes), LY%
(percent of lymphocytes), MO# (number of monocytes),
MO% (percent of monocytes), EO# (number of eosino-
phils), EO% (percent of eosinophils), BA# (number of ba-
sophils), and BA% (percent of basophils) were also
analyzed using a blood cell counter (Hemavet 0950, CDC
Technology, USA). Following the blood collection, the rats
were sacrificed by cervical dislocation and the adrenal
glands, bladder, ovaries, uterus, epididymis, seminal ve-
sicle, heart, thymus, thyroid gland, trachea, esophagus,
tongue, prostate, lungs, nasal cavity, kidneys, spleen, liver,
pancreas, and brain all carefully removed. The organs
were then weighed, fixed in a 10% formalin solution
containing neutral phosphate-buffered saline, embedded
in paraffin, stained with hematoxylin and eosin, and finally
examined using light microscopy. Meanwhile, the testes
were fixed using Bouin’s solution. Two control groups
were used with 5 animals in each, however, the results
were pooled for the analysis in the Additional file 1.
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The organs fixed in 10% formaline solutions for the histo-
pathological evaluation were also used for the tissue silver
determination. The tissues were digested with concen-
trated nitric acid using a microwave digestion system
(MARS 230/60, CEM). Thereafter, the concentration of
silver in the digested fluid was analyzed according to a
flameless method using an atomic absorption spectropho-
tometer equipped with a Zeeman graphite furnace (Perkin
Elmer 5100ZL, Zeeman Furnace Module, USA) based on
the NIOSH 7300 method [12]. The concentration of silver
in the tissues was expressed as the μg/g wet weight. The
detection limit was 0.24 ppb and the limit of quantification
was 0.797 ppb.
Silver clearance from tissues during 4-month recovery
period
The elimination half-life (t1/2) of the silver in the blood
and various biological tissues 1, 2, and 4 months follow-
ing the oral administration of silver nanoparticles was
obtained by analyzing the terminal phase of the silver
concentration vs. the time profiles using the nonlinear
least squares regression software WinNonlin (Pharsight,
Cary, NC, USA).
Statistical analyses
The statistical analyses were performed using SPSS (Ver-
sion 12). The statistical evaluation included a two-tailed
Student’s t-test or analysis of variance (ANOVA) follow-
ing multiple comparison tests using Duncan’s method.
The level of statistical significance was set at p < 0.05.
Results
Silver nanoparticle characterization
The count median diameter and geometric standard de-
viation of the silver nanoparticles in the 0.9% citrate so-
lution (Sodium citrate tribasic dihydrate, Sigma USA)
analyzed by transmission electron microscopy were
10 nm/1.28 and 25 nm/ 2.1, respectively (Figure 1). The
difference in the average size was shown to be significant
(P < 0.01) using a Student t-test. The percentage of silver
ions in the 10 nm and 25 nm silver nanoparticles was
0.0008% and 0.002%, respectively.
Animal observation, food consumption, and effect on
body and organ weights
There were no significant differences in the food con-
sumption and water intake between the treated male
and female rats and the control group (data not shown).
Plus, no significant dose-related changes were observed
in the male body weights during both the silver nanopar-
ticle treatment and the recovery period (Figure 2). How-
ever, the female rats did show body weight differences at
the two-month recovery point between the control andthe middle-dose group with the 10 nm treatment and
between the control and the high and middle-dose
groups with the 25 nm treatment, yet none of these
dose-related changes was statistically significant. There
were no signs of infection or adverse effects during the
recovery period.
Biochemical, hematological, and histopathological
evaluation
The histopathology examinations after 28 days adminis-
tration of 10 nm or 25 nm silver nanoparticles and after
one or two months of recovery did not reveal any dose-
dependent lesions in the liver (Additional file 1: Tables
S1-S6). While the 28-day treatment group and one and
two-month recovery groups did show lipid droplets and
inflammatory cell infiltration in the liver and tubular re-
generation in the kidneys, these observations were not
dose-dependent (Additional file 1: Table S7).
The hematological parameters did not show any
significant changes after 28 days of silver nanoparticle
administration or after one or two months of recovery,
except for a decreased MCHC (mean corpuscular he-
moglobin concentration) in the high-dose female rats
(25 nm) from the one and two-month recovery groups
(Additional file 1: Tables S12 & S13) and a decreased
platelet count in the high-dose female rats (25 nm) from
the two-month recovery group (Additional file 1: Table
S13). The prothrombin time (PT) was significantly
increased (P < 0.05) in the high-dose (25 nm) female rats
when compared with the control (Additional file 1: Table
S14). However, the PT and APPT (active partial throm-
boplastin time) did not show any significant change
in either the male or female rats from the one and
two-month recovery groups (Additional file 1: Tables
S15 & S16).
When compared with the control group, the cholesterol
(CHOL) level was significantly higher (P < 0.05) in the male
rats after being treated with the low or high dose of 10 nm
silver nanoparticles and the low dose of 25 nm silver
nanoparticles for 28 days (Additional file 1: Table S17).
However, this increase returned to a normal level after one
or two months of recovery (Additional file 1: Tables S18 &
S19). The level of inorganic phosphorus was significantly
higher (P < 0.01) in the high-dose (25 nm) male rats after
2 months of recovery (Additional file 1: Table S19). The
level of alkaline phosphatase (ALP) was significantly higher
(P < 0.01) in the female rats treated with the low or high
dose of silver nanoparticles (10 nm) for 28 days (Additional
file 1: Table S20). The level of aspartate aminotransferase
(AST) was significantly higher (P < 0.05) in the high-dose
(25 nm) groups (Additional file 1: Table S20). In addition,
the ALP level was significantly higher (P < 0.01) in the low-
dose (10 nm) female rats after one month of recovery
(Additional file 1: Table S21). However, the AST and ALP
BA
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Figure 1 Particle size distribution and TEM micrographs of silver nanoparticles. A. Particle size distribution. Blue squares, 10 nm; red circles,
25 nm. B. TEM micrographs.
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2 months of recovery (Additional file 1: Table S22). Some
of the increases in the hepatotoxicity-relevant markers
(CHOL, ALP, and AST) following the silver nanoparticle
exposure were consistent with previous observations re-
lated to the subacute and subchronic oral toxicity of silver
nanoparticles. Yet, most of the hepatotoxicity marker levels
returned to normal after 2 months of recovery.
3.4. Silver concentrations in blood, liver, kidneys,
spleen, testes, ovaries, and brain after 4 months of recov-
ery following silver nanoparticle administration.The blood silver concentrations rapidly decreased dur-
ing the first month following the cessation of the silver
nanoparticle administration and then maintained these
levels for the remainder of the 4- month recovery period
(Figure 3). For the 10 nm silver nanoparticles, the blood
silver t1/2 in the high-dose group was 98.94 and
78.14 days for the male and female rats, respectively.
However, for the 25 nm silver nanoparticles, the blood
silver t1/2 in the high-dose group was longer at 133.37














































































































Figure 2 Body weight changes during 28-day oral administration of silver nanoparticles and 1, 2, and 4 months of recovery.
a, Significant difference vs. control, p < 0.05 (3–4 weeks). A. Male (10 nm), 0–4 weeks (n = 20); 5–8 weeks (n = 15); B. Female (10 nm), 0–4 weeks
(n = 20); 5–8 weeks 9–12 weeks (n = 10); 13–20 weeks (n = 5). (n = 15); 9–12 weeks (n = 10); 13–21 weeks (n = 5). C. Male (25 nm), 0–4 weeks
(n = 20); 5–8 weeks (n = 15); D. Female (25 nm), 0–4 weeks (n = 20); 5–8 weeks 9–12 weeks (n = 10); 13–20 weeks (n = 5). (n = 15); 9–12 weeks
(n = 10); 13–21 weeks (n = 5).
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decreased over the 4-month period, showing a rapid de-
crease during 2 months following the cessation of the
silver nanoparticle administration (P < 0.05-0.01) for the
high-dose male and female rats treated with either the
10 nm or 25 nm silver nanoparticles, and the low-dose
female rats treated with the 25 nm silver nanoparticles
(Figure 4). For the male rats, the liver silver t1/2 was
slightly longer for the 25 nm silver nanoparticles than
for the 10 nm silver nanoparticles, however, this was not
the case for the female rats treated with the 10 nm silver
nanoparticles (Table 1).
The kidney silver content persisted for 4 months after
cessation in the high-dose male and female rats treatedwith the 10 nm silver nanoparticles, whereas the silver con-
tent decreased significantly (P < 0.05-0.01) after 1 month in
the low-dose male and female rats treated with the 10 nm
silver nanoparticles (Figure 5). For the rats treated with the
25 nm silver nanoparticles, the kidney silver content de-
creased significantly (P < 0.01) after 1 month in both the
low and high-dose male and female rats, with the exception
of the high-dose female rats that only showed a significant
decrease after 2 months (Figure 5). The kidney silver t1/2 in
the high-dose male rats was slightly longer for the 10 nm
silver nanoparticles than for the 25 nm silver nanoparticles,
while overall the kidney silver t1/2 was slightly longer in the
female rats than in the male rats for both the 10 and 25 nm
silver nanoparticles (Table 1).
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Figure 3 Blood silver concentrations (ng/g tissue wet weight) before and after cessation of silver nanoparticle administration. The rats
were allowed to recover for 1, 2, and 4 months following 28 days of oral silver nanoparticle exposure. A. Male (10 nm). B. Female (10 nm).
C. Male (25 nm). D. Female (25 nm).
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(P < 0.01) decrease after 1 month in the high-dose male
and female rats treated with either the 10 nm or 25 nm sil-
ver nanoparticles, whereas the low-dose male and female
rats treated with the 10 nm or 25 nm silver nanoparticles
showed a relatively slower clearance (Figure 6). The spleen
silver t1/2 was slightly longer for the 25 nm silver nano-
particles than for the 10 nm silver nanoparticles, except in
the case of the low-dose male rats treated with the 25 nm
silver nanoparticles (Table 1).
The ovaries showed a rather longer clearance in the low
and high-dose female rats treated with the 10 nm silver
nanoparticles, only showing a significant (P < 0.01) de-
crease after 4 months of recovery (Figure 7). In contrast,
the ovaries in the high-dose female rats treated with the
25 nm silver nanoparticles showed a significant (P < 0.01)decrease after 1 month of recovery, whereas the ovaries in
the low-dose female rats treated with the 25 nm silver
nanoparticles did not show any significant decrease during
the recovery period. The ovary silver t1/2 was similar in
the low and high-dose female rats treated with the 10 nm
silver nanoparticles, yet longer than the ovary silver t1/2 in
the low-dose female rats treated with the 25 nm silver
nanoparticles (Table 1).
The silver concentrations in the testes did not show any
decrease in the male rats treated with either the 10 nm or
25 nm silver nanoparticles, with the exception of the low-
dose male rats treated with the 10 nm silver nanoparticles
that showed a significant (P < 0.01) decrease after 4 months
of recovery (Figure 7). The testis silver t1/2 was 55.03 days
or 64.59 days for the low-dose male rats treated with
the 10 nm or 25 nm silver nanoparticles, respectively
Table 1 Clearance T1/2 of silver after 28 days of oral administration (superscript 0, 0-order; 1, 1st-order)
Tissue Male Female
100 mg/kg/day 500 mg/kg/day 100 mg/kg/day 500 mg/kg/day
Half life (days) R square Half life (days) R square Half life (days) R square Half life (days) R square
A. 10 nm
Blood0 76.88 0.47 98.94 0.58 77.33 0.47 78.14 0.48
Brain1 260.78 0.96 95.98 0.93 140.23 1.00 77.97 0.88
Kidneys1 29.75 0.94 69.81 0.91 79.60 0.71 77.49 0.89
Liver1 38.58 0.81 24.05 1.00 189.29 0.09 74.70 0.90
Spleen1 48.67 1.00 54.98 0.98 56.11 0.85 56.04 0.89
Testes/ovaries1 55.03 1.00 N/A N/A 34.79 0.95 35.77 0.92
B. 25 nm
Blood0 77.52 0.47 133.27 0.48 141.45 0.47 140.12 0.48
Brain1 136.03 0.77 81.06 0.96 124.08 1.00 60.05 0.90
Kidneys1 32.07 1.00 53.70 0.99 45.60 0.97 87.87 0.82
Liver0 70.10 0.70 62.94 0.82 60.72 0.66 68.29 0.49
Spleen1 30.93 0.99 164.91 0.74 66.32 0.93 66.97 0.94
Testes/ovaries1 64.59 1.00 N/A N/A 61.85 0.84 33.91 0.95
N/A not applicable (Clearance T1/2 not obtainable).
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high-dose male rats treated with the 10 or 25 nm silver
nanoparticles (Table 1).
The brain also showed difficulty clearing the accumu-
lated silver after a prolonged period of recovery. For the
male and female rats treated with the 10 nm or 25 nm
silver nanoparticles, the high-dose male and female rats
showed a significant decrease (P < 0.01) after 4 months
of recovery, except for the high-dose female rats treated
with the 25 nm silver nanoparticles that showed a sig-
nificant decrease (P < 0.01) after 1–2 months of recovery,
whereas the low-dose male and female rats treated with
the 10 nm or 25 nm silver nanoparticles did not show
any clearance (Figure 8). The brain silver t1/2 in the low-
dose male and female rats was longer than that in the
high-dose male and female rats treated with either the
10 nm or 25 nm silver nanoparticles, plus the brain sil-
ver t1/2 for the 10 nm silver nanoparticles was longer
than that for the 25 nm silver nanoparticles (Table 1).
The silver biopersistence in various tissues was further
evaluated by an independent elimination rate parameter,
the mean residence time (MRT), which represents the
mean time the drug molecules reside in the body and is
calculated based on the ratio of AUMC0-tlast/AUC0-tlast,
where AUMC is the area of concentration × time vs. a
time curve, and AUC is the area of concentration vs. a
time curve. As shown in Table 2, the silver MRTs for the
brain and testes/ovaries were longer than those for the
other tissues, suggesting a persistent accumulation of sil-
ver in the brain and testes/ovaries. Also, the particle size
had no significant effect on the MRT.Discussion
The objective of this study was to evaluate the silver clear-
ance from tissues following the cessation of silver nano-
particle administration. The silver concentrations in the
blood rapidly decreased during the first month of recovery
and continued until 4 months, indicating continuous
partitioning from the tissues to the blood. Other tissues,
including the liver, spleen, ovaries, and kidneys, also
showed a degree of clearance of the accumulated silver
during the 4-month recovery period. However, the silver
concentrations in the testes and brain did not decrease to
the control levels, even after the 4-month recovery period,
indicating that silver clearance is difficult across biological
barriers, such as the blood–brain barrier or blood-testis
barrier. The silver half-life in each tissue type was calcu-
lated using a zero-order elimination model (Table 1).
However, since the R2 value was not significantly im-
proved when compared with that calculated using a first-
order elimination model, the zero-order elimination was
only applied to the blood and liver treated with the 25 nm
silver nanoparticles. A half-life estimation based on a
zero-order elimination is primarily dependent on the ini-
tial concentration change. In previous literature, the
systemic disposition of silver has also been described using
first-order inter-compartment rate constants [8]. Yet, a
large inter-subject variability due to destructive sampling
can result in a poor half-life estimation, and inter-
individual variations of silver concentrations in biological
samples are already known to be very high. Thus, the
MRT, which represents the mean residence time of silver
nanoparticles in tissue, would seem to be a better
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Figure 4 Liver silver concentrations (ng/g tissue wet weight) before and after cessation of silver nanoparticle administration. The rats
were allowed to recover for 1, 2, and 4 months following 28 days of oral silver nanoparticle exposure. **, P < 0.01 28-day exposure vs. recovery;
*, P < 0.05 28-day exposure vs. recovery; a, P < 0.05 1-month recovery vs. 2-month recovery; b, P < 0.05 1-month recovery vs. 4-month recovery.
A. Male (10 nm). B. Female (10 nm). C. Male (25 nm). D. Female (25 nm).
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MRT showed similar values, regardless of the dose level,
thereby indicating the biopersistence more clearly than
the t1/2 values.
Although the clearance half-times differed according to
dose and gender, the tissues with no biological barrier, such
as the liver, kidneys, and spleen, showed a similar clearance
trend. Furthermore, the MRT also showed differences
in the silver biopersistence in various tissues. Thus, the sil-
ver concentration clearance was in the order of blood >
liver = kidneys > spleen > ovaries > testes = brain. Therefore,
the silver clearance from tissues containing biological bar-
riers would appear to be differently regulated. As a result,
the silver biopersistence in the testes and brain can compli-
cate the risk assessment of silver nanoparticles. Silverbiopersistence in the brain and testes was already observed
in the case of 28 days of oral administration of silver nitrate
(9 mg/kg bw/day), noncoated (<20 nm), and PVP-coated
silver nanoparticles (90 mg/kg bw/day) followed by 8 weeks
of recovery [9]. However, the short-term (5 days) intraven-
ous injection of various sizes (20, 80, and 110 nm) of silver
nanoparticles followed by 17 days of recovery did not re-
veal any silver biopersistence in the brain and testes [8].
Wijnhoven et al., [13] previously hypothesized that the
toxic effect of silver is proportional to the free silver ions,
yet how this relates to silver nanoparticles remains
unclear. Notwithstanding, the results would seem to indi-
cate two possible ways of clearing accumulated silver from
the body: as silver ions or silver nanoparticles. However,
there are clear difficulties in evaluating the silver ions
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Figure 5 Kidney silver concentrations (ng/g tissue wet weight) before and after cessation of silver nanoparticle administration. The rats
were allowed to recover for 1, 2, and 4 months following 28 days of oral silver nanoparticle exposure. **, P < 0.01 28-day exposure vs. recovery;
*, P < 0.05 28-day exposure vs. recovery; a, P < 0.05 1-month recovery vs. 2-month recovery; b, P < 0.05 1-month recovery vs. 4-month recovery.
A. Male (10 nm). B. Female (10 nm). C. Male (25 nm). D. Female (25 nm).
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ing the fraction of ionization from silver nanoparticle sur-
faces in various tissues.
In the present study, the silver nanoparticles were dis-
persed in citrate after gas-phase synthesis, as described by
Lee et al. [11]. Stabilizing the layers prevents silver nano-
particle aggregation, enabling the nanoparticles to remain
suspended in the water column. Silver nanoparticles are
normally stabilized using a charged surface coating, such
as citrate, that creates an electrostatic barrier to aggrega-
tion. In a natural environment, a stabilizing agent such as
citrate, which is weakly complexed with the silver nano-
particle surfaces, can be rapidly displaced by ligands, such
as sulfides [14]. Surface-bound ligands, such as citrate,
compete with oxygen for surface sites and thus decreasethe rate of oxidation. Liu et al. provided evidence of this
mechanism by demonstrating a decrease in the Ag + re-
leased from silver nanoparticles as the citrate surface coat-
ings became more densely-packed [15]. Nanoparticles in
the GI tract show a different behavior depending on the
pH in the stomach (pH 2–3) and intestines (pH 7.8),
where unstable and agglomerated nanoparticles disperse
well in an acidic and basic pH [16]. Liu et al. recently pro-
posed a conceptual model of ingested silver nanoparticles
in the human body. In their model, argyrial silver deposits
are not translocated engineered Ag-NPs, but rather second-
ary particles formed by partial dissolution in the GI tract
followed by ion uptake, systemic circulation as organo-Ag
complexes, and immobilization as zerovalent Ag-NPs by
photoreduction in light-affected skin regions [17]. The
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Figure 6 Spleen silver concentrations (n/g tissue wet weight) before and after cessation of silver nanoparticle administration. The rats
were allowed to recover for 1, 2, and 4 months following 28 days of oral silver nanoparticle exposure. **, P < 0.01 28-day exposure vs. recovery;
*, P < 0.05 28-day exposure vs. recovery; a, P < 0.05 1-month recovery vs. 2-month recovery; b, P < 0.05 1-month recovery vs. 4-month recovery.
A. Male (10 nm). B. Female (10 nm). C. Male (25 nm). D. Female (25 nm).
Lee et al. Particle and Fibre Toxicology 2013, 10:36 Page 10 of 14
http://www.particleandfibretoxicology.com/content/10/1/36secondary Ag-NPs then undergo detoxifying transfor-
mations into sulfides and further into selenides or Se/S
mixed phases through exchange reactions. The formation
of secondary particles in biological environments implies
that Ag-NPs are not only a product of industrial nanotech-
nology, but have also been long present in the human body
following exposure to more traditional chemical forms of
silver. Therefore, the lack of any difference in tissue distri-
bution between the 10 and 25 nm silver nanoparticles after
28 days of oral administration indicated that the ingested
silver nanoparticles were dissolved in the low pH gastric
fluid environment, which then led to silver ion release. The
silver ions and their complexes are brought into the blood-
stream through ion or nutrient uptake channels and circu-
late systematically. Plus, the majority of silver in the
circulation is predicted to be bound to thiol complexes,which have high binding affinities yet are easily exchange-
able, giving Ag(I) a significant biomolecular mobility [17].
Similarly, in vivo nanoparticle formation from silver ions
has also been suggested following the detection of silver-
containing nanoparticles in several tissues obtained from
animals administered silver nitrate or silver nanoparticles
orally for 28 days [9]. Yet, the uptake of silver nanoparticles
through the intestines cannot be excluded. In a previous
90-day silver nanoparticle (average 56 nm) oral administra-
tion study, a dose-dependent increase in the villi pigmenta-
tion was observed (presumably yet not confirmed as silver
nanoparticle related) [5].
The formaline solution-based tissue preparation used
in the present study did not allow the nanoparticles in
the tissue samples to be examined by TEM. Yet, while
TEM can be used to visualize silver nanoparticles in
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Figure 7 Ovary and testis silver concentrations (ng/g tissue wet weight) before and after cessation of silver nanoparticle
administration. The rats were allowed to recover for 1, 2, and 4 months following 28 days of oral silver nanoparticle exposure. **, P < 0.01 28-day
exposure vs. recovery; *, P < 0.05 28-day exposure vs. recovery; b, P < 0.05 1-month recovery vs. 4-month recovery; c P < 0.05 2-month recovery vs.
4-month recovery. A. Ovaries (10 nm). B. Ovaries (25 nm). C. Testes (10 nm). D. Testes (25 nm).
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http://www.particleandfibretoxicology.com/content/10/1/36tissues, the particle shapes of the silver nanoparticles can-
not be confirmed without the use of additional defining
methodologies, such as EDX (energy dispersive X-ray
analyzer). And even a TEM-EDX analysis may not provide
exact composition information on target particles. Fur-
thermore, the tissue presence of secondary particles gener-
ated from silver-ion complexes can also complicate
whether particles are silver nanoparticles or secondary sil-
ver ion complexes. Thus, other recent technologies, such
as hyperspectral images, need to be used in future studies.
In previous studies, certain forms of Mn (Manganese)
have been reported to affect the brain. For example, in the
case of rats, inhalation exposure to soluble forms of Mn,
such as Mn sulfate and Mn phosphate, was found to in-
crease the brain Mn concentration when compared to in-
halation exposure to the less soluble Mn tetraoxide [18].After the cessation of welding-fume exposure (average
diameter 100 nm), the absence of any further supply of sol-
uble Mn to the lungs resulted in a reduction of the Mn
concentrations in the blood and other tissues, including the
brain, liver, and spleen [19]. However, unlike Mn accumula-
tion in the brain, the silver in this study exhibited a different
pattern, showing poor clearance from brain tissue.
Furthermore, the different nanoparticle sizes used in this
study did not have much effect on the ADME (absorption,
distribution, metabolism, and excretion), although the size
difference was relatively narrow. The distribution and
clearance of silver from various tissues showed a similar
pattern. Similarly, in other studies, the inhalation of 18–
19 nm [6] and 12–15 nm [20] silver nanoparticles and oral
dosing with 56–60 nm silver nanoparticles [4,5] showed a

































































Figure 8 Brain silver concentrations (ng/g tissue wet weight) before and after cessation of silver nanoparticle administration. The rats
were allowed to recover for 1, 2, and 4 months following 28 days of oral silver nanoparticle exposure. **, P < 0.01 28-day exposure vs. recovery;
*, P < 0.05 28-day exposure vs. recovery; b, P < 0.05 1-month recovery vs. 4-month recovery; c P < 0.05 2-month recovery vs. 4-month recovery.
A. Male (10 nm). B. Female (10 nm). C. Male (25 nm). D. Female (25 nm).
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gested by Wijnhoven et al. [18] and chemical transform-
ation suggested by Lie et al. [17], which state that silver
toxicity mainly originates from silver ions, in this case gen-
erated from the surface of the silver nanoparticles.
A certain level of liver toxicity was indicated by the in-
crease of cholesterol (CHOL) in the male rats following
the 28-day oral administration of the low and high dose
of 10 nm silver nanoparticles and low dose of 25 nm sil-
ver nanoparticles, the increase of alkaline phosphatase
(ALP) in the female rats following the low and high dose
of 10 nm silver nanoparticles, and the increase of aspar-
tate aminotransferase (AST) in the female rats following
the high dose of 25 nm silver nanoparticles. While one
case of bile duct hyperplasia was observed among the
male rats treated with the 10 nm silver nanoparticles,the percent of inflammatory cell infiltration in the male
rats was only mildly increased by the 10 nm and 25 nm
silver nanoparticle treatments. The present study did not
observe the more prominent bile duct hyperplasia
reported in a previous 28-day oral study [4] and 90-day
oral study [5]. Thus, the development of bile duct hyper-
plasia may require a longer exposure duration than
28 days.
The present study also found that coating the silver
nanoparticles, in this case with citrate, did not have any
effect on the ADME when compared with the use of un-
coated silver nanoparticles, including silver nanoparticles
generated by evaporation/condensation, as used in other
inhalation toxicity studies [6,17], dry powder, as used in
other oral toxicity studies [4,5], and PVP-coated silver
nanoparticles [9]. When evaluating the toxicity of the
Table 2 Mean residence time (MRT) of silver after 28 days of oral administration
Tissue Male Female
100 mg/kg/day 500 mg/kg/day 100 mg/kg/day 500 mg/kg/day
(days) (days) (days) (days)
A. 10 nm
Blood 2.85 10.02 4.70 11.24
Brain 58.60 54.44 57.82 53.54
Kidneys 31.03 49.12 42.10 49.60
Liver 21.49 32.05 48.77 29.82
Spleen 38.24 43.43 39.52 43.58
Testes/Ovaries 55.32 63.68 44.70 44.19
B. 25 nm
Blood 3.75 6.47 5.53 11.25
Brain 55.06 52.43 58.57 56.93
Kidneys 25.80 34.67 34.33 46.72
Liver 22.40 29.99 33.89 37.42
Spleen 30.75 40.95 48.11 35.81
Testes/Ovaries 55.34 63.31 48.29 41.75
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http://www.particleandfibretoxicology.com/content/10/1/36citrate-coated silver nanoparticles used in this study, the
extent of the toxicity was quite similar to that of the dry
powder used in the previous studies by Kim et al. [4,5].
Thus, when including silver biopersistence, especially in
the brain and testes, this complicates the risk assessment
of silver nanoparticles. Therefore, the NOAELs previously
reported by Kim et al. [5] based on a subchronic oral
toxicity study and Sung et al. [6] based on a subchronic
inhalation toxicity study need to be adjusted in the light of
biopersistence. Until now, histopathological evaluations
of the testes and brain have not show any apparent to-
xicity, consequently, new tools are needed to evaluate
biopersistent-relevant toxicity. Nonetheless, the current
findings of minimized effects from silver nanoparticle
coating and size differences on the ADME could simplify
the risk assessment of silver nanoparticles.Additional file
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